N@N

NOKOMIS, Fla.--([ BUSINESS WIRE ])--With cases of Parkinsonas disease sharply on the rise as the worldas population ages, the costs associated with the illness are rapidly rising, too. Rainbow Biosciences, the biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC) is working on new solutions to help reduce the global costs associated with Parkinsonas and other neurological diseases.

Experts estimate that up to 10 million people worldwide are currently living with Parkinsonas, including as many as one million Americans. An average of 60,000 Americans are diagnosed with the disease each year, but that number doesnat include thousands of cases that go undetected or undiagnosed.

Whatas worse, the numbers are growing.

There is reason for hope, however. RBCC is currently negotiating a definitive agreement with Amarantus Biosciences (OTCBB: AMBS), a company that could be on the verge of revolutionary new diagnostic and therapeutic tools for Parkinsonas patients and their doctors.

RBCC is working to deliver breakthroughs like these to the people who need them most. The market for Parkinsonas drugs could grow to a value of $3.75 billion by 2015, according to a report last year by Visiongain.

For more information on RBCCas biotechnology initiatives, please visit [ www.rainbowbiosciences.com/investors.html ].

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB:RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [[ www.RainbowBioSciences.com ]]. For investment information and performance data on the company, please visit [ www.RainbowBioSciences.com/investors.html ].

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.